10-Q: Medifast Q3 2025: Revenue Plunges Amid Coach Decline

Medifast reported a significant revenue decline and net loss in Q3 2025, driven by a substantial decrease in active earning OPTA VIA coaches and ongoing market challenges.

Summary

• Revenue for the three months ended September 30, 2025, decreased by 36.2% to $89.4 million from $140.2 million in the prior year period.
• The company reported a net loss of $2.3 million, or $(0.21) per diluted share, for Q3 2025, compared to a net income of $1.1 million, or $0.10 per diluted share, in Q3 2024.
• For the nine months ended September 30, 2025, revenue fell 35.7% to $310.7 million from $483.5 million in the comparable period of 2024.
• The net loss for the nine months ended September 30, 2025, was $0.6 million, or $(0.05) per diluted share, a decrease from a net income of $1.3 million, or $0.12 per diluted share, in the same period last year.
• The number of active earning OPTA VIA coaches decreased by 35.0% to 19,500 as of September 30, 2025, from 30,000 a year prior.
• Average revenue per active earning OPTA VIA coach declined by 1.9% to $4,585 for Q3 2025, compared to $4,672 for Q3 2024.
• Gross profit margin decreased to 69.5% in Q3 2025 from 75.4% in Q3 2024, primarily due to loss of leverage on fixed costs and a reserve for product reformulation.
• Selling, general, and administrative (SG&A) expenses decreased by $37.3 million, or 36.0%, in Q3 2025, mainly due to lower coach compensation and reduced marketing and collaboration costs.
• The company sold all its holdings in LifeMD common stock during Q2 2025, realizing a $3.2 million gain for the nine months ended September 30, 2025.
• Medifast is executing a strategic transformation focused on metabolic health and a return to growth, including new product innovations and tailored programs for GLP-1 users.

Sentiment

Score: 2

Explanation: The sentiment is significantly negative due to substantial declines in revenue, net income (shifting to a loss), and a critical operational metric (active coaches). While strategic initiatives are mentioned, the current financial performance indicates severe headwinds and challenges in the core business model.

Positives

• Cash and cash equivalents increased to $99.5 million at September 30, 2025, from $90.9 million at December 31, 2024.
• Total cash, cash equivalents, and investment securities increased to $173.5 million at September 30, 2025, from $162.3 million at December 31, 2024.
• Realized a $3.2 million gain on the sale of LifeMD common stock for the nine months ended September 30, 2025.
• Strategic initiatives are underway to address market challenges, including a focus on metabolic health, new product development, and tailored programs for GLP-1 medication users.
• Launched new coach support programs like EDGE and Premier+ to enhance client acquisition and retention.

Negatives

• Revenue decreased significantly by 36.2% for the three months and 35.7% for the nine months ended September 30, 2025.
• Reported a net loss of $2.3 million for Q3 2025 and $0.6 million for the nine months ended September 30, 2025, compared to net income in the prior year periods.
• Operating income turned into a loss of $4.1 million for Q3 2025 and $6.4 million for the nine months ended September 30, 2025.
• The number of active earning OPTA VIA coaches declined by 35.0% year-over-year to 19,500.
• Average revenue per active earning OPTA VIA coach decreased by 1.9% in Q3 2025, continuing a downward trend since Q3 2022.
• Gross profit margin decreased by 590 basis points in Q3 2025 due to lower volumes, loss of leverage on fixed costs, and a $1.6 million reserve for product reformulation.
• Net cash flow provided by operating activities decreased by $17.3 million to $12.1 million for the nine months ended September 30, 2025.
• Allowance for obsolete inventory increased to $3.993 million at September 30, 2025, from $1.445 million at December 31, 2024.
• Management determined that performance-based share awards granted in March 2024 would not reach predetermined goals, leading to a $1.2 million reversal of compensation expense.

Risks

• Continued decline in active earning OPTA VIA coaches and client acquisition due to market competition and the rapid adoption of GLP-1 medications.
• Macroeconomic conditions, including inflation and tariffs, could impact cost structure and consumer spending.
• Intense competition within the weight loss industry from commercial programs, pharmaceutical products (like GLP-1s), surgical interventions, and digital solutions.
• Potential for material adverse effects on results of operations, financial position, or cash flows from the unfavorable resolution of legal actions, though none are currently expected to be material.
• Challenges in effectively integrating GLP-1 medication users into existing programs and developing compelling offerings for this segment.

Future Outlook

The company plans to launch significant product innovations incorporating next-generation ingredients for metabolic enhancement next year. It is also taking an intentional and methodical approach to tailoring program offerings for three specific client categories, including individuals using GLP-1 medications and those managing weight after stopping them. Medifast expects to continue fueling coach productivity and growth through initiatives like the new EDGE program and the refreshed Premier+ auto-ship program, launched in July 2025, and by enhancing digital tools.

Management Comments

• We are currently executing a strategic transformation focused on metabolic health and a return to growth strategy by fueling coach productivity and coach growth.
• Medifast stands at the forefront of evidence-based wellness solutions and its coach-first model creates an opportunity for coaches' individual businesses, and has a flywheel effect as new clients join, which drives revenue and leads to new active earning coaches joining, which leads to more new clients and generates further revenue.
• We continue to innovate and build upon our scientific and clinical heritage to fulfill our mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
• Medifast's weight loss and metabolic health experts unveiled Metabolic Synchronization, a breakthrough approach that reverses metabolic dysfunction through a targeted reset, and is aimed to drive future innovation.
• We believe our coach-based model is scalable and drives both client success and growth, and is a key competitive advantage.

Industry Context

The weight loss industry is highly competitive, facing significant disruption from the surging awareness and popularity of GLP-1 medications. Medifast acknowledges these medications as a major competitor but sees strong alignment with its expertise in helping people create durable habits through coach-supported, behavior-based systems, especially since GLP-1s are most effective when paired with lifestyle changes. The company is adapting its offerings to cater to individuals using GLP-1s, those coming off them, and those preferring coach-supported habit-based programs, positioning itself within the evolving metabolic health landscape.

Comparison to Industry Standards

• GLP-1 medications are identified as a major competitor, prompting a huge change in consumer thinking about weight loss solutions.
• Research indicates approximately one-third of GLP-1 users discontinue medication after six months, and as many as 74% stop after a year, with two-thirds of weight lost typically regained within 12 months of stopping treatment.
• The company highlights that its comprehensive plan activated strong and targeted fat burn to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass, and protecting muscle.
• In a clinical study, the group on the OPTA VIA 5 & 1 Plan lost 17 times more fat than the self-directed control group, and clients with a coach lost 10 times more weight.

Legal Proceedings

• The company is subject to a variety of litigation and similar proceedings arising from the ordinary course of business.
• Management does not believe these proceedings will have a material adverse effect on results of operations, financial position, or liquidity, but acknowledges that results cannot be predicted with certainty.

Related Party Transactions

• The company previously invested $10 million in LifeMD, Inc. common stock, which was fully sold during the second quarter of 2025, resulting in a $3.2 million gain for the nine months ended September 30, 2025.
• LifeMD provided services to stand-up the collaboration between LifeMD and the Company, with $0.0 million recognized in SG&A for services performed by LifeMD for the nine months ended September 30, 2025, compared to $5.0 million in the prior year period.
• The collaboration between LifeMD and the Company continues and remains unchanged despite the sale of equity holdings.

Stakeholder Impact

• Shareholders: Negative impact due to significant revenue decline, net losses, and decreased earnings per share. Future share price likely to be negatively affected.
• Coaches: The substantial decrease in active earning coaches (35%) indicates challenges in the core direct-selling model, despite new programs like EDGE and Premier+ designed to support them.
• Clients: New tailored programs and product innovations are being developed to address diverse needs, including those using GLP-1 medications, potentially offering more relevant solutions.
• Employees: Operational adjustments and strategic transformation may lead to changes in roles or organizational structure, though no specific employee impacts were detailed.
• Creditors: The termination of the credit agreement and maintenance of a strong cash position suggest no immediate liquidity concerns, but sustained losses could impact creditworthiness long-term.

Next Steps

• Launch significant product innovations incorporating next-generation ingredients for metabolic enhancement next year.
• Continue to tailor program offerings for three specific client categories, including GLP-1 users.
• The new office space lease in Baltimore, Maryland, is expected to commence in March 2026.
• The company will not renew its current office space lease when it expires in February 2026.
• Actively monitor the impact of macroeconomic developments on the business and update practices accordingly.
• Evaluate potential acquisitions that complement the business, though no present understandings or commitments exist.

Key Dates

Recommendation

The filing reveals a severe deterioration in Medifast's core business, marked by a 36.2% revenue decline in Q3, a shift from net income to significant net losses, and a 35% reduction in active coaches. While strategic initiatives are in place to address market shifts, particularly the rise of GLP-1 medications, the immediate financial and operational headwinds are substantial and indicate a challenging path to recovery. The declining coach network, coupled with reduced revenue per coach, suggests fundamental issues in client acquisition and retention. Investors should consider these significant negative trends and the uncertainty surrounding the effectiveness of new strategies in a highly competitive and evolving market.

Keywords

Medifast, OPTAVIA, weight loss, metabolic health, GLP-1 medications, direct selling, health and wellness, Q3 2025, financial results, SEC filing, 10-Q, coach network, revenue decline, net loss